Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
August 31, 2023
Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer
Article links to www.globenewswire.com
September 27, 2023
Sitryx raises additional $39 million to progress development of disease-modifying therapeutics
Article links to prn.to
October 3, 2023
The Oxford-Harrington Rare Disease Centre Launches
Article links to www.beacontx.com
June 12, 2023
Beacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases
Article links to innovation.ox.ac.uk
May 22, 2023
Oxford University retains No. 1 spot for spinouts
Article links to www.ultromics.com
April 26, 2023
Ultromics granted FDA Breakthrough Device Designation
Article links to www.caristo.com
April 17, 2023
Caristo Diagnostics Completes Series A Financing and Welcomes New CEO
Article links to quantummotion.tech
February 21, 2023
Quantum Motion Raises £42 Million Investment Round
All News
28•11•23
Portfolio News
Theolytics
Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer
09•06•23
Portfolio News
Theolytics
Theolytics presents data on THEO-260 and THEO-310 at ASCO and EHA
05•10•22
Portfolio News
Theolytics
Theolytics presents CAF-targeting therapy for stromal rich tumours and strengthens leadership team
31•05•22
Portfolio News
Theolytics
Theolytics' £1m project with Innovate UK to develop a novel therapy for multiple myeloma patients
07•07•21
Portfolio News
Theolytics
Theolytics expands Series A financing and welcomes M Ventures as a new investor
06•01•21
Portfolio News
Theolytics
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal